RA Capital Management 13F holdings, Q2 2023
Holdings as of June 30, 2023 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 54 US equity positions worth $5.3bn in its Q2 2023 13F filing. The largest position was ASND at 18.9% of the reported book, followed by LEGN and PCVX. Against the Q1 2023 filing, it opened 3 new positions, added to 8 and reduced 2 among the top 50 holdings.
What did RA Capital Management own in Q2 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2023 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 18.9% | $1.0bn | 11,225,357 | 61% | added |
| 2 | LEGN LEGEND BIOTECH CORP | Healthcare | 8.2% | $432.5m | 6,264,707 | 157% | added |
| 3 | PCVX VAXCYTE INC | Healthcare | 7.4% | $394.1m | 7,891,254 | 8% | added |
| 4 | DICE THERAPEUTICS INC | 6.9% | $365.0m | 7,856,612 | 0% | held | |
| 5 | 89BIO INC | 4.1% | $216.4m | 11,416,948 | 0% | held | |
| 6 | BIIB BIOGEN INC | Healthcare | 2.9% | $151.8m | 532,892 | 0% | held |
| 7 | AEROVATE THERAPEUTICS INC | 2.7% | $141.7m | 8,263,982 | 0% | held | |
| 8 | VRNA VERONA PHARMA PLC | 2.5% | $133.6m | 6,317,990 | 0% | held | |
| 9 | CUREVAC N V | 2.4% | $127.6m | 12,245,955 | 0% | held | |
| 10 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.3% | $123.2m | 7,236,454 | 0% | held |
| 11 | NEWAMSTERDAM PHARMA COMPANY | 2.0% | $107.0m | 9,000,000 | 125% | added | |
| 12 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 2.0% | $105.0m | 12,297,721 | -8% | reduced |
| 13 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.9% | $102.9m | 8,670,644 | 0% | held |
| 14 | GERN GERON CORP | Healthcare | 1.9% | $101.3m | 31,544,806 | 0% | held |
| 15 | INHIBRX INC | 1.9% | $100.0m | 3,853,867 | 0% | held | |
| 16 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.8% | $93.6m | 5,676,067 | 3% | added |
| 17 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.8% | $93.2m | 7,809,852 | 11% | added | |
| 18 | RXST RXSIGHT INC | Healthcare | 1.7% | $87.9m | 3,052,796 | 0% | held |
| 19 | COGT COGENT COMMUNICATIONS HLDGS | Healthcare | 1.4% | $76.0m | 6,416,147 | 7% | added |
| 20 | PEPG PEPGEN INC | Healthcare | 1.4% | $72.7m | 8,131,952 | 0% | held |
| 21 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.4% | $71.9m | 1,000,000 | – | new |
| 22 | AVIDITY BIOSCIENCES INC | 1.3% | $71.2m | 6,416,998 | 0% | held | |
| 23 | VOR VOR BIOPHARMA INC | 1.3% | $70.3m | 22,748,880 | 0% | held | |
| 24 | GHRS GH RESEARCH PLC | 1.3% | $66.3m | 5,587,333 | 0% | held | |
| 25 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.2% | $62.6m | 17,202,009 | 0% | held |
| 26 | ACRV ACRIVON THERAPEUTICS INC | 1.2% | $62.3m | 4,810,508 | 0% | held | |
| 27 | ICOSAVAX INC | 1.1% | $59.2m | 5,963,565 | 0% | held | |
| 28 | ITEOS THERAPEUTICS INC | 1.1% | $58.5m | 4,417,259 | 0% | held | |
| 29 | 4D MOLECULAR THERAPEUTICS IN | 1.0% | $55.5m | 3,069,531 | – | new | |
| 30 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.0% | $54.2m | 3,178,476 | 0% | held |
| 31 | ALPINE IMMUNE SCIENCES INC | 0.9% | $48.2m | 4,691,178 | 0% | held | |
| 32 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.9% | $47.8m | 2,007,946 | 0% | held |
| 33 | ABOS ACUMEN PHARMACEUTICALS INC | 0.9% | $47.0m | 9,770,773 | 0% | held | |
| 34 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 0.9% | $45.6m | 4,398,453 | 0% | held |
| 35 | IMMUNOGEN INC | 0.8% | $44.0m | 2,329,958 | -89% | reduced | |
| 36 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.8% | $43.3m | 2,122,465 | 0% | held |
| 37 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.7% | $38.3m | 11,609,704 | 0% | held |
| 38 | CLYM ELIEM THERAPEUTICS INC | 0.7% | $36.8m | 13,150,849 | 0% | held | |
| 39 | TNYA TENAYA THERAPEUTICS INC | 0.7% | $35.6m | 6,067,483 | 0% | held | |
| 40 | ANTX AN2 THERAPEUTICS INC | 0.6% | $32.1m | 3,773,517 | 0% | held | |
| 41 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.6% | $31.9m | 1,762,000 | 0% | held |
| 42 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 0.6% | $29.3m | 3,370,506 | 0% | held |
| 43 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.4% | $20.2m | 3,009,678 | 0% | held |
| 44 | HOWL WEREWOLF THERAPEUTICS INC | 0.4% | $18.7m | 6,144,881 | 0% | held | |
| 45 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.4% | $18.7m | 2,971,231 | 0% | held |
| 46 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.3% | $18.0m | 3,426,286 | 0% | held |
| 47 | BLACK DIAMOND THERAPEUTICS I | 0.3% | $17.8m | 3,525,754 | 36% | added | |
| 48 | NKTX NKARTA INC | Healthcare | 0.3% | $17.1m | 7,805,129 | 0% | held |
| 49 | CELC CELCUITY INC | Healthcare | 0.3% | $15.4m | 1,400,001 | 0% | held |
| 50 | IGM BIOSCIENCES INC | 0.2% | $8.7m | 937,500 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.